Tofacitinib en el tratamiento de la colitis ulcerosa: Casos clínicos

Translated title of the contribution: Tofacitinib for the treatment of ulcerative colitis. Report of two cases

Rodrigo Quera, Lilian Flores, Paulina Núñez, Patricio Ibáñez*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.

Translated title of the contributionTofacitinib for the treatment of ulcerative colitis. Report of two cases
Original languageSpanish
Pages (from-to)1039-1043
Number of pages5
JournalRevista Medica de Chile
Issue number7
StatePublished - Jul 2020

Bibliographical note

Publisher Copyright:
© 2020 Sociedad Medica de Santiago. All rights reserved.


  • Inflammatory Bowel Diseases
  • Janus Kinases
  • Therapeutics
  • Ulcerative colitis


Dive into the research topics of 'Tofacitinib for the treatment of ulcerative colitis. Report of two cases: Casos clínicos'. Together they form a unique fingerprint.

Cite this